List of Tables
Table 1. Global VEGF Inhibitors for Cancer Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global VEGF Inhibitors for Cancer Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global VEGF Inhibitors for Cancer Market Competitive Situation by Manufacturers in 2025
Table 4. Global VEGF Inhibitors for Cancer Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global VEGF Inhibitors for Cancer Sales Market Share by Manufacturers (2021–2026)
Table 6. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global VEGF Inhibitors for Cancer Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market VEGF Inhibitors for Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of VEGF Inhibitors for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of VEGF Inhibitors for Cancer, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of VEGF Inhibitors for Cancer, Product Types and Applications
Table 12. Global Key Manufacturers of VEGF Inhibitors for Cancer, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global VEGF Inhibitors for Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on VEGF Inhibitors for Cancer Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global VEGF Inhibitors for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global VEGF Inhibitors for Cancer Sales by Region (K Units), 2021–2026
Table 18. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2021–2026)
Table 19. Global VEGF Inhibitors for Cancer Sales by Region (K Units), 2027–2032
Table 20. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2027–2032)
Table 21. Global VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2021–2026
Table 22. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2021–2026)
Table 23. Global VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2027–2032
Table 24. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2027–2032)
Table 25. North America VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 27. North America VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 28. North America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 29. North America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 30. Europe VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 32. Europe VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 33. Europe VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 34. Europe VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific VEGF Inhibitors for Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific VEGF Inhibitors for Cancer Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific VEGF Inhibitors for Cancer Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 42. Latin America VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 43. Latin America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 50. Global VEGF Inhibitors for Cancer Sales (K Units) by Type (2021–2026)
Table 51. Global VEGF Inhibitors for Cancer Sales (K Units) by Type (2027–2032)
Table 52. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021–2026)
Table 53. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2027–2032)
Table 54. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Type (2021–2026)
Table 55. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Type (2027–2032)
Table 56. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021–2026)
Table 57. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2027–2032)
Table 58. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Type (2021–2026)
Table 59. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Type (2027–2032)
Table 60. Global VEGF Inhibitors for Cancer Sales (K Units) by Application (2021–2026)
Table 61. Global VEGF Inhibitors for Cancer Sales (K Units) by Application (2027–2032)
Table 62. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021–2026)
Table 63. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2027–2032)
Table 64. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Application (2021–2026)
Table 65. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Application (2027–2032)
Table 66. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021–2026)
Table 67. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2027–2032)
Table 68. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Application (2021–2026)
Table 69. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Application (2027–2032)
Table 70. Sanofi Company Information
Table 71. Sanofi Description and Business Overview
Table 72. Sanofi VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Sanofi VEGF Inhibitors for Cancer Product
Table 74. Sanofi Recent Developments/Updates
Table 75. Roche Company Information
Table 76. Roche Description and Business Overview
Table 77. Roche VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Roche VEGF Inhibitors for Cancer Product
Table 79. Roche Recent Developments/Updates
Table 80. Eli Lilly Company Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Eli Lilly VEGF Inhibitors for Cancer Product
Table 84. Eli Lilly Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Pfizer VEGF Inhibitors for Cancer Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Celltrion Healthcare Company Information
Table 91. Celltrion Healthcare Description and Business Overview
Table 92. Celltrion Healthcare VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Celltrion Healthcare VEGF Inhibitors for Cancer Product
Table 94. Celltrion Healthcare Recent Developments/Updates
Table 95. Amgen Company Information
Table 96. Amgen Description and Business Overview
Table 97. Amgen VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Amgen VEGF Inhibitors for Cancer Product
Table 99. Amgen Recent Developments/Updates
Table 100. Amneal Pharmaceuticals Company Information
Table 101. Amneal Pharmaceuticals Description and Business Overview
Table 102. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product
Table 104. Amneal Pharmaceuticals Recent Developments/Updates
Table 105. Chia Tai Tianqing Company Information
Table 106. Chia Tai Tianqing Description and Business Overview
Table 107. Chia Tai Tianqing VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Chia Tai Tianqing VEGF Inhibitors for Cancer Product
Table 109. Chia Tai Tianqing Recent Developments/Updates
Table 110. Qilu Pharma Company Information
Table 111. Qilu Pharma Description and Business Overview
Table 112. Qilu Pharma VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Qilu Pharma VEGF Inhibitors for Cancer Product
Table 114. Qilu Pharma Recent Developments/Updates
Table 115. Boan Biotech Company Information
Table 116. Boan Biotech Description and Business Overview
Table 117. Boan Biotech VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Boan Biotech VEGF Inhibitors for Cancer Product
Table 119. Boan Biotech Recent Developments/Updates
Table 120. Jiangsu Hengrui Pharmaceuticals Company Information
Table 121. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 122. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product
Table 124. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 125. SinoCellTech Company Information
Table 126. SinoCellTech Description and Business Overview
Table 127. SinoCellTech VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. SinoCellTech VEGF Inhibitors for Cancer Product
Table 129. SinoCellTech Recent Developments/Updates
Table 130. Innovent Company Information
Table 131. Innovent Description and Business Overview
Table 132. Innovent VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Innovent VEGF Inhibitors for Cancer Product
Table 134. Innovent Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. VEGF Inhibitors for Cancer Distributors List
Table 138. VEGF Inhibitors for Cancer Customers List
Table 139. VEGF Inhibitors for Cancer Market Trends
Table 140. VEGF Inhibitors for Cancer Market Drivers
Table 141. VEGF Inhibitors for Cancer Market Challenges
Table 142. VEGF Inhibitors for Cancer Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of VEGF Inhibitors for Cancer
Figure 2. Global VEGF Inhibitors for Cancer Market Value by Type (US$ Million), 2021–2032
Figure 3. Global VEGF Inhibitors for Cancer Market Share by Type: 2025 & 2032
Figure 4. Ramucirumab Product Picture
Figure 5. Aflibercept Product Picture
Figure 6. Ramucirumab Product Picture
Figure 7. Other Product Picture
Figure 8. Global VEGF Inhibitors for Cancer Market Value by Application (US$ Million), 2021–2032
Figure 9. Global VEGF Inhibitors for Cancer Market Share by Application: 2025 & 2032
Figure 10. Metastatic colorectal cancer
Figure 11. Metastatic Non-small Cell Lung Cancer
Figure 12. Recurrent Glioblastoma
Figure 13. Cervical Cancer
Figure 14. Other
Figure 15. Global VEGF Inhibitors for Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global VEGF Inhibitors for Cancer Market Size (US$ Million), 2021–2032
Figure 17. Global VEGF Inhibitors for Cancer Sales (K Units), 2021–2032
Figure 18. Global VEGF Inhibitors for Cancer Average Price (US$/Unit), 2021–2032
Figure 19. VEGF Inhibitors for Cancer Report Years Considered
Figure 20. VEGF Inhibitors for Cancer Sales Share by Manufacturers in 2025
Figure 21. Global VEGF Inhibitors for Cancer Revenue Share by Manufacturers in 2025
Figure 22. Top 5 and Top 10 Global VEGF Inhibitors for Cancer Players: Market Share by Revenue in VEGF Inhibitors for Cancer in 2025
Figure 23. VEGF Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 24. Global VEGF Inhibitors for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 25. North America VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 26. North America VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 27. United States VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Canada VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Europe VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 30. Europe VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 31. Germany VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. France VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. U.K. VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Italy VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Russia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Asia Pacific VEGF Inhibitors for Cancer Sales Market Share by Region (2021–2032)
Figure 37. Asia Pacific VEGF Inhibitors for Cancer Revenue Market Share by Region (2021–2032)
Figure 38. China VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Japan VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. South Korea VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. India VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Australia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. China Taiwan VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Southeast Asia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Latin America VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 46. Latin America VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 47. Mexico VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Brazil VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Argentina VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Colombia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Middle East and Africa VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 52. Middle East and Africa VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 53. Turkey VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Saudi Arabia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. UAE VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Global Sales Market Share of VEGF Inhibitors for Cancer by Type (2021–2032)
Figure 57. Global Revenue Market Share of VEGF Inhibitors for Cancer by Type (2021–2032)
Figure 58. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Type (2021–2032)
Figure 59. Global Sales Market Share of VEGF Inhibitors for Cancer by Application (2021–2032)
Figure 60. Global Revenue Market Share of VEGF Inhibitors for Cancer by Application (2021–2032)
Figure 61. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Application (2021–2032)
Figure 62. VEGF Inhibitors for Cancer Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
